Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 2,675 shares of the stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $36.13, for a total value of $96,647.75. Following the sale, the chief financial officer now owns 21,004 shares of the company's stock, valued at $758,874.52. This represents a 11.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Yajing Chen also recently made the following trade(s):
- On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The stock was sold at an average price of $30.00, for a total transaction of $288,540.00.
- On Friday, April 4th, Yajing Chen sold 924 shares of Zai Lab stock. The shares were sold at an average price of $33.11, for a total value of $30,593.64.
- On Wednesday, April 2nd, Yajing Chen sold 5,280 shares of Zai Lab stock. The stock was sold at an average price of $35.89, for a total value of $189,499.20.
Zai Lab Trading Down 4.0%
Shares of ZLAB traded down $1.45 during trading hours on Friday, reaching $34.74. 759,523 shares of the stock traded hands, compared to its average volume of 1,054,456. Zai Lab Limited Unsponsored ADR has a 52-week low of $16.01 and a 52-week high of $44.34. The company has a market cap of $3.83 billion, a P/E ratio of -13.95 and a beta of 0.96. The company's 50-day moving average price is $33.35 and its two-hundred day moving average price is $31.02.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The firm had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%. On average, research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.
Analyst Ratings Changes
A number of research analysts recently issued reports on ZLAB shares. Bank of America reissued a "neutral" rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th. Scotiabank assumed coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th.
Get Our Latest Analysis on ZLAB
Institutional Investors Weigh In On Zai Lab
A number of institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE boosted its position in shares of Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after acquiring an additional 5,534 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Zai Lab in the 4th quarter worth $1,032,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Zai Lab during the 4th quarter valued at about $1,674,000. Daiwa Securities Group Inc. grew its position in shares of Zai Lab by 44.7% during the fourth quarter. Daiwa Securities Group Inc. now owns 13,833 shares of the company's stock valued at $362,000 after purchasing an additional 4,276 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Zai Lab by 39.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 841,735 shares of the company's stock worth $22,045,000 after purchasing an additional 237,582 shares during the last quarter. 41.65% of the stock is owned by hedge funds and other institutional investors.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
